89bio (ETNB) provided a corporate update and business outlook for 2025. Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia; topline 26-week data expected in the second half of 2025. The Phase 3 ENLIGHTEN program in patients with non-cirrhotic and compensated cirrhotic metabolic dysfunction-associated steatohepatitis continues to enroll patients across both trials. Cash, cash equivalents, and marketable securities totaled approximately $440 million as of December 31, 2024
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener